A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

Abstract
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.
Funding Information
  • NIH (award309186, K08CA166039)